E-Cigarettes: No Definitive Evidence on Their Potential Cardiovascular Effect, but Some Suggest Caution

E-cigarettes may bring about cardiac risk according to a new literature review soon to be published in J Am Coll Cardiol. The evidence on potential harm is not definitive, but some experts suggest caution in their use until there is more solid evidence.

E-cigarettes have been advertised as a healthy alternative to traditional cigarettes and an aid for tobacco cessation, but recent evidence suggests that they might cause adverse cardiovascular events.

 

Such events involve endothelial function, vascular stiffness, vasoconstriction, heart rate, blood pressure, inflammation, oxidative stress, and platelet function (all of which have already been observed with e-cigarettes). While e-cigarettes are widely believed to be safe (in terms of both cardiovascular risk and cancer), the truth is that they have not been studied enough. In fact, we could say that there is not enough solid evidence confirming that e-cigarettes even help people to quit smoking conventional cigarettes.


Read also: Several Features Define a Hostile Neck in AAA patients, but Only One Makes the Difference.


These devices can only be considered another tool to help people quit smoking.

 

If they do help smokers to quit conventional cigarettes, their potential for public health benefit is huge. However, this potential benefit must be balanced against their long-term health risks, which are still unknown.

 

Researchers reviewed 14 studies (all of them carried out in developed countries) that suggest possible cardiovascular harm and note that e-cigarettes are available in most countries around the world without any regulation.


Read also: Early Strut Coverage and Its Implications for Dual Antiplatelet Therapy.


We have a responsibility to inform our patients that e-cigarettes contain chemicals whose long-term effects are currently unknown. For smokers, this may be the lesser evil, but we should emphasize the fact that we still lack enough evidence.

 

Original title: 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment.

Reference: Barua RS et al. J Am Coll Cardiol. 2018; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...